Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$7.04 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
11.35 million
Earnings per share
-3.223
Dividend per share
N/A
Year To Date Return
-31.11%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
⏸️ Investing
These 3 ASX shares just raced to 52-week highs: Can they keep going?
⏸️ Investing
Here's why these 4 ASX shares have surged higher today
⏸️ Investing
Why the Zelda Therapeutics Ltd share price has surged higher today
⏸️ Investing
My Top 5 Investing Predictions for the Rest of 2017
⏸️ Investing
Here's why these 4 ASX shares have surged higher today
⏸️ Investing
These 3 ASX shares just hit all-time highs: Can they go higher?
⏸️ Investing
Why these 4 ASX shares have SMASHED the market today
⏸️ Investing
Here's why these 6 explosive ASX shares have smashed the market in March
⏸️ Investing
Why these 4 ASX shares have started the week with a BANG
⏸️ Investing
Why these 4 ASX shares have soared today
⏸️ Investing
Zelda Therapeutics Ltd's share price rockets: Is the pot stock a buy?
⏸️ Investing
Why the marijuana sector is at risk of becoming a joke
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
ZLD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 19 Dec 2024 | $0.62 | $0.01 | 1.64% | 6,916 | $0.62 | $0.70 | $0.62 |
| 18 Dec 2024 | $0.61 | $0.01 | 1.67% | 2,343 | $0.61 | $0.61 | $0.61 |
| 17 Dec 2024 | $0.60 | $0.00 | 0.00% | 146 | $0.60 | $0.60 | $0.60 |
| 16 Dec 2024 | $0.60 | $0.00 | 0.00% | 486 | $0.60 | $0.60 | $0.60 |
| 13 Dec 2024 | $0.60 | $0.00 | 0.00% | 516 | $0.60 | $0.60 | $0.60 |
| 12 Dec 2024 | $0.60 | $0.00 | 0.00% | 577 | $0.60 | $0.60 | $0.60 |
| 11 Dec 2024 | $0.60 | $0.00 | 0.00% | 272 | $0.56 | $0.60 | $0.56 |
| 10 Dec 2024 | $0.60 | $-0.01 | -1.64% | 3,460 | $0.63 | $0.63 | $0.60 |
| 09 Dec 2024 | $0.61 | $0.00 | 0.00% | 1,604 | $0.61 | $0.61 | $0.61 |
| 06 Dec 2024 | $0.61 | $0.00 | 0.00% | 349 | $0.61 | $0.61 | $0.61 |
| 05 Dec 2024 | $0.61 | $-0.01 | -1.61% | 8,153 | $0.64 | $0.64 | $0.56 |
| 04 Dec 2024 | $0.62 | $0.00 | 0.00% | 2,302 | $0.62 | $0.62 | $0.62 |
| 03 Dec 2024 | $0.62 | $0.05 | 8.77% | 2,679 | $0.59 | $0.62 | $0.59 |
| 02 Dec 2024 | $0.57 | $-0.08 | -12.31% | 10,765 | $0.65 | $0.65 | $0.56 |
| 29 Nov 2024 | $0.65 | $0.00 | 0.00% | 16 | $0.66 | $0.66 | $0.65 |
| 28 Nov 2024 | $0.65 | $0.03 | 4.80% | 4,077 | $0.63 | $0.65 | $0.63 |
| 27 Nov 2024 | $0.63 | $-0.02 | -3.13% | 5,782 | $0.64 | $0.64 | $0.63 |
| 26 Nov 2024 | $0.64 | $-0.01 | -1.55% | 2,327 | $0.65 | $0.65 | $0.64 |
| 25 Nov 2024 | $0.65 | $0.01 | 1.56% | 2,335 | $0.64 | $0.65 | $0.64 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
|
| Dr Oludare Odumosu | Managing Director | Dec 2019 |
Dr Odumosu has over 10 years of experience in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a unique combination of experiences from several academic, public health and life science organisations.
|
| Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualised and established GlaxoSmithKline Ventures and was its founding Vice President.
|
| Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain.
|
| Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organisations, universities, and life science companies, including Cephalon Pharmaceuticals.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malik Majeed | 1,134,644 | 10.00% |
| Quincy Street Capital Llc | 456,622 | 4.02% |
| Sharri J Rochlin <Rochlin Family Resource A/C> | 393,168 | 3.46% |
| Mr Zoltan Kerekes | 393,168 | 3.46% |
| Osagie Imasogie | 393,168 | 3.46% |
| Sunset Capital Management Pty Ltd <Sunset Superfund A/C> | 383,725 | 3.38% |
| Ms Lisa Gray | 381,988 | 3.37% |
| Mera I Llc\C | 332,479 | 2.93% |
| Muller Ct Pty Ltd <Muller Super Fund A/C> | 312,126 | 2.75% |
| Mr Torsten M Geers <The Torsten M Geers Living A/C> | 307,454 | 2.71% |
| Mr Steve Shapiro | 302,571 | 2.67% |
| Mara Gordon | 252,242 | 2.22% |
| Mr Saul Shorr and Mrs Margaret Shorr | 151,285 | 1.33% |
| Dr Chanda Latrice Macias | 146,479 | 1.29% |
| Mera Ii Llc\C | 133,372 | 1.18% |
| Oludare Odumosu | 131,766 | 1.16% |
| Citicorp Nominees Pty Limited | 128,727 | 1.13% |
| Mr Daniel Hexter and Mrs Shannon Hexter | 103,389 | 0.91% |
| Geers Egag Llc | 85,715 | 0.76% |
| Connie H Katz and Samuel P Katz | 78,063 | 0.69% |
